Natus Medical Incorporated

NasdaqGS:NTUS Stock Report

Market Cap: US$1.1b

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Natus Medical Past Earnings Performance

Past criteria checks 2/6

Key information

9.7%

Earnings growth rate

9.5%

EPS growth rate

Medical Equipment Industry Growth8.9%
Revenue growth rate-1.4%
Return on equity2.9%
Net Margin2.7%
Last Earnings Update31 Mar 2022

Recent past performance updates

We Like Natus Medical's (NASDAQ:NTUS) Earnings For More Than Just Statutory Profit

Aug 13
We Like Natus Medical's (NASDAQ:NTUS) Earnings For More Than Just Statutory Profit

Recent updates

Novanta to replace Six Flags Entertainment in S&P MidCap 400, Six Flags to replace Natus Medical in S&P SmallCap 600

Jul 22

Some Investors May Be Worried About Natus Medical's (NASDAQ:NTUS) Returns On Capital

Mar 04
Some Investors May Be Worried About Natus Medical's (NASDAQ:NTUS) Returns On Capital

Some Investors May Be Worried About Natus Medical's (NASDAQ:NTUS) Returns On Capital

Nov 08
Some Investors May Be Worried About Natus Medical's (NASDAQ:NTUS) Returns On Capital

We Like Natus Medical's (NASDAQ:NTUS) Earnings For More Than Just Statutory Profit

Aug 13
We Like Natus Medical's (NASDAQ:NTUS) Earnings For More Than Just Statutory Profit

Does Natus Medical (NASDAQ:NTUS) Have A Healthy Balance Sheet?

Aug 02
Does Natus Medical (NASDAQ:NTUS) Have A Healthy Balance Sheet?

We Think Shareholders Are Less Likely To Approve A Pay Rise For Natus Medical Incorporated's (NASDAQ:NTUS) CEO For Now

Jun 10
We Think Shareholders Are Less Likely To Approve A Pay Rise For Natus Medical Incorporated's (NASDAQ:NTUS) CEO For Now

Breakeven Is Near for Natus Medical Incorporated (NASDAQ:NTUS)

May 05
Breakeven Is Near for Natus Medical Incorporated (NASDAQ:NTUS)

Is Natus Medical (NASDAQ:NTUS) Using Debt Sensibly?

Feb 15
Is Natus Medical (NASDAQ:NTUS) Using Debt Sensibly?

Breakeven Is Near for Natus Medical Incorporated (NASDAQ:NTUS)

Jan 11
Breakeven Is Near for Natus Medical Incorporated (NASDAQ:NTUS)

Reflecting on Natus Medical's (NASDAQ:NTUS) Share Price Returns Over The Last Five Years

Dec 07
Reflecting on Natus Medical's (NASDAQ:NTUS) Share Price Returns Over The Last Five Years

Revenue & Expenses Breakdown
Beta

How Natus Medical makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

NasdaqGS:NTUS Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Mar 224781316957
31 Dec 214731317158
30 Sep 214641716757
30 Jun 21452216458
31 Mar 21421-1115658
31 Dec 20416-1715661
30 Sep 20428-1916464
30 Jun 20449-117264
31 Mar 204901118363
31 Dec 19495-1618959
30 Sep 19505-3018956
30 Jun 19512-4419257
31 Mar 19517-5020459
31 Dec 18531-2320761
30 Sep 18521-1820760
30 Jun 18513-2120856
31 Mar 18505-2420655
31 Dec 17501-2020152
30 Sep 17477-319049
30 Jun 174451917245
31 Mar 174193415138
31 Dec 163824313633
30 Sep 163744113431
30 Jun 163783913431
31 Mar 163743813531
31 Dec 153763813430
30 Sep 153704013230

Quality Earnings: NTUS has a large one-off loss of $7.4M impacting its March 31 2022 financial results.

Growing Profit Margin: NTUS became profitable in the past.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: NTUS's earnings have grown by 9.7% per year over the past 5 years.

Accelerating Growth: NTUS has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Earnings vs Industry: NTUS has become profitable in the last year, making it difficult to compare its past year earnings growth to the Medical Equipment industry (12.9%).


Return on Equity

High ROE: NTUS's Return on Equity (2.9%) is considered low.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.